<DOC>
	<DOCNO>NCT02187627</DOCNO>
	<brief_summary>This study design obtain basic information three PET image tracer develop detect tau pathology brain . In study , healthy control participant participant AD study . Information collect include brain plasma kinetics , tissue distribution ( brain ) , radiation dosimetry , test-retest variability signal brain . The study consist Part 1 , Part 2A , Part 2B . During Part 1 , image data assess ongoing basis base data , one tracer prioritize two tracer . The tracer select investigated Part 2A Part 2B .</brief_summary>
	<brief_title>Evaluation 11CRO6924963 , 11CRO6931643 , 18FRO6958948 Tracers Positron Emission Tomography ( PET ) Imaging Tau Healthy Alzheimer 's Disease ( AD ) Participants</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion Criteria All Participants Agreement use highly effective contraception measure If participant concomitant medication , indication dosage medicine stable least 4 week prior study start expectation relevant change use dose occur throughout study Body mass index ( BMI ) 18 32 kilogram per square meter ( kg/m^2 ) Weight less equal ( &lt; /= ) 300 pound ( lb ) Inclusion Criteria Healthy Control Participants Healthy `` young '' control participant age 2540 year healthy `` elderly '' control participant age great equal ( &gt; /= ) 50 year Normal cognitive function , include normal Mini Mental State Examination ( MMSE ) score judged investigator Healthy control participant participate Part 2B : must less ( &lt; ) 195 centimeter ( cm ) ( 6 foot , 5 inch ) tall order accommodate whole body scan Inclusion Criteria Participants Diagnosis Probable AD Diagnosis probable AD , accord National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association criteria Participants age &gt; /= 50 year A study partner able accompany participant visit answer question participant MMSE score 16 26 , inclusive Exclusion Criteria All Participants History presence neurological diagnosis AD may influence outcome analysis scan result ; examples include limited stroke , traumatic brain injury , space occupy lesion , nonAlzheimer 's tauopathies , Parkinson 's disease Participants medical history include know autosomal dominant AD mutation amyloid precursor protein ( APP ) presenilin ( PS1 , PS2 ) mutation gene cause type autosomal dominant familial dementia History presence clinically relevant hematological , hepatic , respiratory , cardiovascular , renal , metabolic , endocrine , central nervous system disease medical condition well control , may put participant risk , could interfere objective study , make participant unsuitable participation study reason opinion principal investigator Clinically relevant pathological finding physical examination , electrocardiogram , laboratory value screen assessment could interfere objective study Known history clinically significant infectious disease include acquire immunodeficiency syndrome ( AIDS ) serological indication acute/chronic hepatitis B C human immunodeficiency virus infection Pregnancy lactation Unsuitable vein repeat venipuncture Current symptom allergy and/or severe allergy drug medical history Alcohol consumption average &gt; 3 drink daily regular smoker ( &gt; 10 cigarette , &gt; 3 pipeful , &gt; 3 cigar per day ) Coffee ( tea ) consumption &gt; 10 cup per day methylxanthinecontaining drink &gt; 1.5 liter per day ( L/day ) Have receive investigational medication within last 3 month 5 time ( x ) elimination halflife , whichever longer , prior Day 1 ( i.e. , enrollment ) Exclusion Criteria Related Trial Procedures Presence pacemaker ; aneurysm clip ; artificial heart valve ; ear implant ; foreign metal object eye , skin , body , circumstance ( e.g . claustrophobia ) would contraindicate magnetic resonance imaging ( MRI ) scan For participant Part 1 Part 2A , contraindication arterial cannulation Exclusion Criterion Participants Probable Alzheimer 's Disease Has receive treatment target amyloidbeta tau within last 24 month</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>